Moderna, Inc. (MRNA)

Moderna's stock price has significantly declined over the past year. Key events impacting the stock include continued revenue decline and net losses, cost-cutting initiatives, RSV vaccine approval and modest sales, flu vaccine updates with a delayed timeline for the combination vaccine, analyst ratings and price target adjustments, COVID-19 vaccine market normalization, and insider trading activity.

Demand for Moderna's products, especially its COVID-19 vaccine, is seasonal, with higher demand expected in the second half of the year, as reflected in lower first-quarter sales.

Moderna, Inc. is a biotechnology company specializing in mRNA-based vaccines and therapeutics. Its core business uses mRNA technology to instruct cells to produce proteins that prevent or fight diseases. Major products include Spikevax (COVID-19 vaccine) and mRESVIA (RSV vaccine). The company has a robust pipeline targeting various diseases, with 34 development candidates across 44 programs, and 41 in clinical studies as of early 2025.

Moderna's primary operations and research facilities are in the United States, with its headquarters in Cambridge, Massachusetts, and other locations across the country. Globally, Moderna has a commercial presence in 11 countries and plans to expand to ten more in Asia-Pacific and Europe. It also supplies its COVID-19 vaccine to 92 Gavi COVAX AMC countries and has manufacturing partnerships across Europe, with plans to build a new factory in Africa.

Moderna has maintained a strong reputation as a top employer and through brand awareness campaigns, but has faced challenges due to the political weaponization of its COVID success, scrutiny over stock sales and patent disputes, and concerns over side effects in RSV vaccine trials.

Moderna's ownership is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 73.29% to 77.73% of the stock, insiders hold around 7.78%, and public companies and retail investors own approximately 21.96% to 33.26%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and Baillie Gifford & Co. Moderna's CEO and other executives are among the top insider shareholders.